Mavacoxib
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525604

CAS#: 170569-88-7

Description: Mavacoxib is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.


Chemical Structure

img
Mavacoxib
CAS# 170569-88-7

Theoretical Analysis

MedKoo Cat#: 525604
Name: Mavacoxib
CAS#: 170569-88-7
Chemical Formula: C16H11F4N3O2S
Exact Mass: 385.05
Molecular Weight: 385.337
Elemental Analysis: C, 49.87; H, 2.88; F, 19.72; N, 10.91; O, 8.30; S, 8.32

Price and Availability

Size Price Availability Quantity
50mg USD 150 Ready to ship
100mg USD 250 Ready to ship
200mg USD 450 Ready to ship
500mg USD 950 Ready to ship
1g USD 1650 Ready to ship
2g USD 2950 Ready to ship
5g USD 6550 Ready to ship
Bulk inquiry

Synonym: PHA-739521; PHA739521; PHA 739521; PHA 739,521; PHA739,521; PHA-739,521; Mavacoxib. trade name Trocoxil.

IUPAC/Chemical Name: 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

InChi Key: TTZNQDOUNXBMJV-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

SMILES Code: O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(F)C=C3)C=C1)(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Mavacoxib is a cyclooxygenase-2 (COX-2) inhibitor.
In vitro activity: The anti-tumourigenic effects of the selective, long-acting COX-2 inhibitor mavacoxib were evaluated. Mavacoxib was cytotoxic to a panel of human and canine osteosarcoma, mammary and bladder carcinoma cancer cell lines; it induced apoptosis and inhibited the migration of these cells. Interestingly, mavacoxib exerted these effects independently of elevated COX-2 expression. These results suggest that mavacoxib may be an effective anti-cancer agent independent of tumour COX-2 expression. Reference: Vet Comp Oncol. 2019 Jun;17(2):194-207. https://onlinelibrary.wiley.com/doi/abs/10.1111/vco.12470
In vivo activity: Mavacoxib and meloxicam were compared in the management of canine OA (osteoarthritis). In all, 111 dogs with OA of the elbow, hip or stifle were randomly assigned to receive one of these NSAIDs for a 12-week period. Outcomes, including ground reaction forces and three validated clinical metrology instruments, were measured at baseline, 6 and 12 weeks. Improvements were seen in all outcome measures for both groups to a similar degree, and adverse events occurred at a similar rate. There were significant improvements in outcome measures from week 6 to week 12, as well as from baseline. Long-term meloxicam dose was more important than recent dose. Clinical efficacy and adverse event rates were similar for meloxicam and mavacoxib. Reference: Vet Rec. 2014 Sep 20;175(11):280. https://bvajournals.onlinelibrary.wiley.com/doi/abs/10.1136/vr.102435

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Ethanol 77.0 199.82

Preparing Stock Solutions

The following data is based on the product molecular weight 385.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Hurst EA, Pang LY, Argyle DJ. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207. doi: 10.1111/vco.12470. Epub 2019 Mar 13. PMID: 30767381. 2. Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ. The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Vet Res. 2014 Sep 5;10:184. doi: 10.1186/s12917-014-0184-9. PMID: 25190452; PMCID: PMC4172958. 3. Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec. 2014 Sep 20;175(11):280. doi: 10.1136/vr.102435. Epub 2014 May 23. PMID: 24859353.
In vitro protocol: 1. Hurst EA, Pang LY, Argyle DJ. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207. doi: 10.1111/vco.12470. Epub 2019 Mar 13. PMID: 30767381. 2. Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ. The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Vet Res. 2014 Sep 5;10:184. doi: 10.1186/s12917-014-0184-9. PMID: 25190452; PMCID: PMC4172958.
In vivo protocol: 1. Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec. 2014 Sep 20;175(11):280. doi: 10.1136/vr.102435. Epub 2014 May 23. PMID: 24859353.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Payne-Johnson M, Becskei C, Chaudhry Y, Stegemann MR. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Vet Rec. 2015 Mar 14;176(11):284. doi: 10.1136/vr.102397. Epub 2014 Nov 27. PubMed PMID: 25433056; PubMed Central PMCID: PMC4392193.
2: Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, Stegemann M. Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. J Vet Pharmacol Ther. 2015 Feb;38(1):1-14. doi: 10.1111/jvp.12185. Epub 2014 Nov 21. Review. PubMed PMID: 25413929.
3: Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ. The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Vet Res. 2014 Sep 5;10:184. doi: 10.1186/s12917-014-0184-9. PubMed PMID: 25190452; PubMed Central PMCID: PMC4172958.
4: Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec. 2014 Sep 20;175(11):280. doi: 10.1136/vr.102435. Epub 2014 May 23. PubMed PMID: 24859353.
5: Cox SR, Liao S, Payne-Johnson M, Zielinski RJ, Stegemann MR. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11. doi: 10.1111/j.1365-2885.2010.01183.x. PubMed PMID: 21219337.
6: Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, Marsh S, Fielder A, Stegemann MR. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. J Vet Pharmacol Ther. 2010 Oct;33(5):461-70. doi: 10.1111/j.1365-2885.2010.01165.x. PubMed PMID: 20840390.